The Experts in Animal Health

Brakke Consulting’s
Animal Health News & Notes for February 25, 2022
Copyright © Brakke Consulting
Editor: Lynn Fondon DVM MBA


Brakke Consulting News
Brakke Recruiting – open position for equine veterinarian
2022 Industry Overview

 Earnings News

Other News
Arden Grange
Aristo Oy
Assisi Pet Care
Boehringer Ingelheim
Clinvet US
Company of Animals
Eclipse Ventures
Forerunner Ventures
Pilgrim’s Pride
Starbar Products
Voff Premium Pet Food

Brakke Consulting
Unique opportunity in Asia for equine veterinarians:
Head of Veterinary Clinical Services

Salary $325,000-375,000 plus annual bonus

Lead a team of equine surgeons, technicians, stable and support staff, ensuring world-class racing via excellent veterinary clinical services. Responsibilities include setting realistic budgets and ensuring operational adherence; creating a culture of cross-functional collaboration, integrity, accountability and respect; maintaining facility & equipment safety and security; providing research and training opportunities for local students via coordination with local veterinary school. Requirements include a primary degree in veterinary science from a recognized university and a minimum of ten years in experience in managing a large equine clinical practice, as well as fluency in both written and spoken English.

Click here for more details.


  • Elanco Animal Health reported its financial results for the full year 2021. Revenue was $4,765 million, an increase of 46% including $1,311 million of incremental revenue from Bayer Animal Health products in 2021. Reported net loss was $(472) million compared to a loss of $(560) million in 2020. (company press release)
  • Dechra Pharmaceuticals reported results for the first half of FY2022 ended December 31, 2021. Revenues were GBP 332.4 million ($452.5 million), a year-over-year increase of 11%. Profit was GBP 40.7 million ($55 million), a 75% year-over-year increase. The North American pharmaceuticals division reported revenues of GBP 126.3 million ($172 million), an increase of 21%. (IHS Markit Connect)
  • Covetrus reported results for the full year 2021. Net sales were $4,575 million, a year-over-year increase of 5%. North American net sales for the year were $2,719 million, an increase of 14%. Growth was driven in part by continued growth in prescription management in North America, partially offset by a decline in sales in Europe, driven by the Company’s U.K. and German businesses. Net loss for the year was $(54) million compared to a loss of $(19) million in 2020. (company press release)
  • ImmuCell Corporation announced its unaudited financial results for the full year 2021. Total product sales increased by 25% to $19.2 million. Net operating income was $257,000 compared to a net operating loss of ($1.4) million during 2020. (company press release)
  • Intervacc reported results for the year 2021. Net sales were up 9.6% to SEK5.2m ($540,000); operating loss was SEK29.4m ($3.0 million). (IHS Markit Connect)
  • Aquaculture health company Benchmark reported results for its fiscal first quarter ended December 31, 2021. Turnover was GBP 40 million ($54.3 million), an increase of 38%. Benchmark’s net loss for the first quarter of 2022 widened to GBP (5.1) million. (IHS Markit Connect)

Brakke Consulting
Announcing the 2022 Brakke Industry Overview

Presented at WVC: Monday, March 7th, 2-4 pm, Four Seasons Hotel, Acacia Ballroom

We are back to being in person!  Come join us at Brakke Consulting’s annual Industry Overview presented at VMX and WVC in 2022. The Overview will feature industry and top global company performance, brand new market research from companion animal veterinarians, and a closer look at the current and future use of monoclonal antibodies in veterinary medicine.

Brand new this year – led by Brakke Senior Consultant Paul Casady, a panel of industry leaders will discuss their views on the outlook for the companion animal market, so you can hear firsthand from these experts.  Panelists for WVC will include:

– Mr. Randolph Legg, President and Head of Commercial Business, Boehringer Ingelheim Animal Health USA
– Mr. Steve Shell, President, MWI Animal Health
– Mr. Greg Hartmann, Chief Executive Officer, NVA

Sign up today using this link, or email Amanda McDavid or call her at 336-396-3916.  Pre-registration cost is $399; there are discounts for multiple attendees from the same company.  We look forward to seeing you there!

  • Starbar Products announced the launch of Inhibidor Insecticidal Pour-On (Diflubenzuron, Piperonyl Butoxide, Lambda-cyhalothrin) for cattle. (Feedstuffs)
  • Likarda announced an R&D agreement with eQcell in the area of equine cell therapies. The deal allows eQcell to evaluate Likarda’s Core-Shell Spherification (CSS) encapsulation technology with its cells in osteoarthritic horses, and to exercise options for a worldwide license. (IHS Markit Connect)
  • Scandinavian ChemoTech’s Animal Care division Vetiqure AB subsidiary announced it has signed its first commercial contract for the US veterinary market. The contract with a veterinary practice includes access to the vetIQure TSE device during an initial evaluation period and a commercial purchase of the company’s treatment kits. (
  • JBS announced that it has withdrawn its previously announced proposal to acquire all of the outstanding shares of common stock of Pilgrim’s Pride Corporation (PPC) that are not already owned by JBS or its subsidiaries. The company withdrew its offer after it was unable to reach an agreement with the PPC Board of Directors regarding the terms of the proposed transaction. (Feedstuffs)
  • Dutch, a subscription-based veterinary telemedicine platform, announced it has raised $20 million in Series A funding led by Forerunner Ventures and Eclipse Ventures. (
  • PupPod and Company of Animals announced a strategic licensing agreement to expand sales of the PupPod Rocker and Feeder to the UK, Canada and Australia. (company press release)
  • Clinvet US announced it has acquired a stake in RTI, LLC (Research Technology Innovation), a Contract Research Organization specializing in conducting pre-clinical trials in food animals. Financial terms were not disclosed. (company press release)
  • EU Boehringer Ingelheim Animal Health announced that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency adopted by majority a positive opinion for the authorization of RenuTend (tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells). The injectable therapy is designed to improve healing of injuries of tendons and suspensory ligaments in horses. Boehringer acquired Belgian start-up Global Stem cell Technology (GST) in August 2020. (IHS Markit Connect)
  • EU German pet food platform AlphaPet announced it has acquired UK-based Arden Grange. The takeover will allow the German company to position itself as a global player in the European region. Financial terms were not disclosed. (GlobalPets)
  • EU Voff Premium Pet Food announced the acquisition of Aristo Oy, a Finnish manufacturer of natural chews and treats. The acquisition is the seventh Voff has done since its launch in 2014. Financial terms were not disclosed. (Petfood Industry)
  • EU Assisi Pet Care announced it has acquired Polish dog treat producer Maced. Financial terms were not disclosed. (GlobalPets)




  • US – BIRD WELFARE The USDA’s Animal and Plant Health Inspection Service (APHIS) is inviting public comments on a proposal to amend the Animal Welfare Act (AWA) regulations to establish new regulations and standards governing the humane handling, care, treatment, and transportation of birds. The proposed regulations would apply to captive birds not bred for use in research. Click here for more information. (USDA)
  • UK – VACCINE RESEARCH Pirbright researchers have been awarded GBP 389,089 ($530,000) to develop a Nipah virus vaccine that could protect pigs and prevent disease in humans. The funding was provided by the government’s UK Vaccine Network and will be delivered by Innovate UK as part of GBP 10 million of UK aid funding advancing research into vaccines. (Feedstuffs)

Last week we asked about your vacation plans.  81% of you say you’re planning a trip that includes flying, and 14% will be driving somewhere.  Only 5% are planning a staycation.  Sounds like most folks are ready to venture further afield for vacation.

This week

We tend to think of our industry as fairly stable in terms of employment longevity – people may move from company to company (or your company’s name may change thanks to an acquisition/merger), but many of us in animal health are long-haulers.  Let’s see if this is the case with our readers.

How long have you been a part of the veterinary/animal health industry?


en_USEnglish (United States)